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Abstract Osteosarcoma is the most common type of bone
cancer in children and adolescents. MicroRNAs (miRNAs)
play important roles in the development, differentiation, and
function of different cell types and in the pathogenesis of
various human diseases. miRNAs are differentially expressed
in normal and cancer cells. The investigation of miRNA ex-
pression between healthy subjects and patients with osteosar-
coma is crucial for future clinical trials. In this study, the ex-
pression levels of miRNAs were detected by qRT-PCR.
Correlation between expression levels of tow miRNAs and
different clinicopathological characteristics were analyzed
using the χ2 test. Survival rate was detected using the log-
rank test and Kaplan–Meier method. qRT-PCR was shown
that expression levels of miR-29b and miR-422a were strong-
ly decreased in osteosarcoma bone tissue compared with non-
cancerous bone tissues. Our result indicated that the low
expression levels of miR-29b and miR-422a showed strong
correlation with large tumor size (P=0.20; 0.029), advanced
TNM stage (P=0.001; 0.012), distant metastasis (P=0.008;
0.019), and grade of tumor (P=0.009; 0.016). Kaplan–Meier
survival analysis showed that the low expressions ofmiR-29b/
miR-422a were correlated with shorter time overall survival
(log-rank test, P=0.009; P=0.013). Moreover, multivariate
Cox proportional hazards model indicated that miR-29b and
miR-422a (P=0.024; P=0.016) were independent prognostic
markers of overall survival of patients. Our result indicated
that downregulation of miR-29b and miR-422a may be linked
to the prediction of poor prognosis, indicating that miR-29b
and miR-422a may be a valuable prognostic marker for oste-
osarcoma patients.
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Introduction
Osteosarcoma (OS) is a destructive primary bone tumor in
children and adolescents that is a tumor with high metastatic
potential [1, 2]. Despite advances of therapeutic strategies
such as surgery and chemotherapy, long time survival rate of
patients suffering from advanced osteosarcoma remains very
low to date [3, 4]. Therefore, it is required to identify bio-
markers, molecular mechanisms, and therapeutic targets for
osteosarcoma. MicroRNAs (miRNAs) are small, non-coding
RNAmolecules that are significant markers for prognosis and
diagnosis of cancer and promising targets for treatment.
miRNAs have important roles in a number of biological func-
tions such as embryogenesis, cell fate specification, cellular
proliferation, differentiation, and apoptosis through alteration
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of the targets expression by both downregulation and up-
regulation [5, 6]. Dysregulation of different microRNAs
has been reported in various human cancers [6, 7]. It is
clear that they can function either as tumor-suppressor or
oncogene in different human malignancies depending on
their target mRNAs [8, 9]. Nevertheless, the roles of
miRNAs in biology of cancer are still required to be stud-
ied. Downregulation of miR-29b has been suggested in
many kinds of cancer, and most of the mentioned studies
focused on the mechanism by which miR-29b acts as
inhibitor of tumorigenesis [10, 11, 12]. A recent study
indicated that miR-422a was downregulated in OS tissues,
and it could be a valuable diagnostic and predictive mark-
er [13]. However, the roles of miR-29b and miR-422a in
osteosarcoma and their relationship with clinicopatholog-
ical factors need further investigation. We aimed the ex-
pression pattern of miR-29b and miR-422a in osteosarco-
ma tissues and their relationship with clinicopathological
factors.
Materials and methods
Patients and clinical specimens
We recruited 51 patients with osteosarcoma from different hos-
pitals in Tehran, Iran, between April 2009 and December 2014.
In addition, adjacent normal bone tissues were also collected.
Patients underwent surgery without chemotherapy or ra-
diotherapy before surgery. Clinical data was obtained from
the database of the patients. The tissues were obtained from
surgical specimens reviewed by pathologist. All the speci-
mens were stored at −80 °C until use. This study was con-
firmed by the research ethics committee, and the clinicopath-
ological features were categorized in Table 1.
Quantitative reverse transcriptase PCR
We used quantitative real-time PCR to assess the expression
level of miR-29b and miR-422a in osteosarcoma patients and
Table 1 The relationship of miR-29b and miR-422a expression with clinicopathological factors of osteosarcoma
Clinicopathological features No. of cases (51) Expression of miR-29b expression of miR-422a P value of miR-29b P value of miR-422a
Low=31 High=20 Low=29 High=22
Gender
Male 30 18 12 19 11 0.672 0.618
Female 21 13 8 10 11
Age
Children, adolescents 20 13 7 15 5 0.528 0.412
Young adults 31 18 13 14 17
Tumor diameter (cm)
≤5 33 14 19 18 15 0.020 0.029
>5 18 17 1 11 7
Location
Distal 24 13 11 10 14 0.412 0.406
Proximal 27 18 9 17 10
Tumor grade
Low 22 11 11 10 12 0.009 0.016
High 29 20 9 19 10
Histological type
Osteoblastic 23 14 9 13 10 0.454 0.483
Chondroblastic 14 8 6 8 6
Telangiectatic 10 6 4 5 5
Fibroblastic 4 3 1 3 1
TNM stage
I+II 34 15 19 14 20 0.001 0.012
III+IV 17 16 1 15 2
Distant metastasis
Yes 18 13 5 13 5 0.008 0.019
No 33 18 15 16 17
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normal tissues. In brief, total RNAwas extracted from tissues
using TRIzol reagent (Invitrogen, Carlsbad, CA). The expres-
sion levels of miRNAs were quantitated using the TaqMan
miRNA assay kit (Applied Biosystems). Real-time PCR was
performed using Rotor Gene 6000 Real-Time PCR (Qiagen,
Germany) with an Invitrogen kit and a TaqMan universal PCR
master mix was also applied. U6 snRNA was utilized as an
endogenous control. Fold change expression of miRNAs were
calculated using ΔΔ-CT method (ΔΔCt=ΔCttumor
samples–ΔCtcontrol sample).
Statistical analysis
All data presented as mean±SD. SPSS 18.0 software
(SPSS Inc., USA) were used to analyze all variables.
Differences between groups were evaluated using
Student’s t test. Moreover, the relationship between
miRNA expression and various clinicopathological fac-
tors was analyzed using the χ2 test. Survival time was
followed up to the date of death, and survival rate was
determined using the log-rank test and Kaplan–Meier
method. Prognostic values of clinicopathological factors
were evaluated using Cox proportional hazards model.
P<0.05 was statistically significant.
Results
Downregulation of miRNAs
The expression levels of miR-29b and miR-422a in patients
were compared with those of adjacent normal bone tissues.
qRT-PCR has shown that expression levels of miR-29b and
miR-422a were strongly decreased in osteosarcoma bone tis-
sue (mean±SD, 3.17±1.39; 1.74±0.57) compared with non-
cancerous bone tissues (mean±SD, 9.67±2.55; 6.16±1.03;
P=0.001; P=0.006; Fig. 1).
Association with clinicopathologic features
The patients were divided into low- and high-expression
groups according to the median expression level.
Donregulation of miR-29b and miR-422a expression levels
showed strong correlation with large tumor size (P=0.20;
0.029), advanced TNM stage (P=0.001; 0.012), distant me-
tastasis (P=0.008; 0.019), and grade of tumor (P=0.009;
0.016).
No significant correlation was found between miR-29b/
miR-422a expression levels and age groups (P=0.528;
0.412), gender (P=0.672; 0.618), location (P=0.412; 0.406),
and histological type (P=0.454; 0.483; Table 1).
Association of miRNA expression with prognosis
in patients
The low expressions of miR-29b/miR-422a were correlated
with shorter time overall survival (log-rank test, P=0.009;
P=0.013; Figs. 2 and 3) based on Kaplan–Meier survival
analysis. According to the multivariate Cox proportional haz-
ards model, miR-29b and miR-422a (P=0.024; P=0.016)
were independent prognostic markers for overall survival of
patients (Tables 2 and 3)
Discussion
To date, there are no available biomarkers routinely utilized that
have diagnostic and predictive values. Therefore, more specific
prognostic biomarkers are required for advancing the therapeutic
strategies for osteosarcoma patients. qRT-PCR has shown that
expression levels of miR-29b and miR-422a were strongly de-
creased in osteosarcoma bone tissue compared with noncancer-
ous bone tissues. Moreover, decreased expression of miR-29b
andmiR-422a was strongly linked to large tumor size, advanced
Fig. 2 Correlation between miR-29b expression and survival time in
patients
Fig. 1 The relative expression of miRNAs in osteosarcoma tissues and
their corresponding normal samples
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TNM stage distant metastasis, and grade of tumor. These result
indicated that low expression of miRNAs may be correlated
with progression of osteosarcoma. Dysregulation of different
microRNAs has been suggested in osteosarcoma tissues [7, 14,
15, 16]. Previous studies have reported that miR-29b was down-
regulated in many kinds of cancer [11, 12, 17, 18]. MiR-29b
directly regulatesVEGF as tumor-suppressive gene, a chaperone
involved in the tumorigenesis in osteosarcoma tissues. It has
reported that restoration of miR-29b inhibited cell proliferation,
migration, and invasion in cancer. Cheng et al. suggested that
miR-29b has oncogenic potential and targets the TET2 gene,
which acts as tumor-suppressor frequently mutated in hemato-
poietic malignancies [18]. It has been reported that miR-29b
functions as a regulator in many kinds of cancers, through its
targeting. It acts as a tumor-suppressor and inhibits cell prolifer-
ation, differentiation, metastasis, and chemosensitivity [19]. On
the other hand, Gougelet et al. suggested that miR-422a was
downregulated in OS tissues, and it could be a valuable diag-
nostic and predictive marker [13]. There have been some studies
which indicated that miR-422a play an important role in human
diseases. Previous studies indicated that decreased expression of
miR-422amay play a protective role in colorectal tumor and can
act as inhibitor of pathways that stimulate tumor cell prolifera-
tion in osteosarcoma [19, 20]. In the current study, the low
expressions of miR-29b/miR-422a were correlated with shorter
time overall survival based on Kaplan–Meier survival analysis.
Multivariate Cox proportional hazards model showed that miR-
29b and miR-422a were independently correlated with overall
survival of patients, suggesting that these miRNAs could be as
independent prognostic factor of overall survival in patient suf-
fering from osteosarcoma.
In conclusion, our result indicated that downregulation of
miR-29b and miR-422a may be linked to the prediction of
poor prognosis, indicating that miR-29b and miR-422a may
be a valuable prognostic marker for osteosarcoma patients.
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